Despite mixed phase 3 showing, Apellis hopes to push eye disorder drug past FDA’s finish line

Apellis Pharmaceuticals’ pegcetacoplan posted mixed results in two late-stage trials studying the C3 inhibitor in patients living with geographic atrophy (GA). Despite the mixed showing, CEO Cedric Francois thinks the med’s performance was strong enough to warrant an FDA nod.  Apellis studied pegcetacoplan, also sold as Empaveli, in two phase 3 trials, known as Oaks and Derby,… Read More »

AHA News: Neurologist Wakes Up in the Hospital Where She Works – As a Stroke Survivor

WEDNESDAY, Sept. 8, 2021 (American Heart Association News) — Dr. Dipika Aggarwal sat in a Kansas City, Kansas, diner on a Tuesday afternoon two years ago sipping coffee and enjoying a mushroom omelet and toast. Only a month before, the neurologist had returned to work after going through surgery, radiation and chemotherapy for stage 4… Read More »